Skip to main content

Arcutis Biotherapeutics, Inc.

ARQT
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001787306

In the last 90 days, Arcutis Biotherapeutics, Inc. insiders filed 0 open-market purchases and 12 sales; 272 institutions reported holding it in 13F filings for Q2 2026, worth $3.45B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Arcutis Biotherapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
12 filings
5 insiders, $2.30M in total
Insiders trading
5
Net value
−$2.30M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Arcutis Biotherapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Arcutis Biotherapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Matsuda MasaruSee Remarks112,508Sep 18, 20269
Welgus Howard G.Director35,841Sep 17, 202613
Curran TerrieDirector23,526Aug 28, 20263
Burnett PatrickSee Remarks117,592Aug 21, 202612
Watanabe Todd FranklinSee Remarks717,203Aug 5, 20268
Peetz ChristopherDirector4,315Jul 17, 20261
Lin Sue-JeanDirector27,567Jun 17, 20263
Heron Patrick JDirector32,213Jun 12, 20261
Leonard Keith RDirector27,901Jun 9, 20263
Gilbert Halley EDirector27,901Jun 9, 20262
Munshi AmitDirector9,799Jun 9, 20262
Krishnamohan NehaDirector27,901Jun 9, 20262
Vairavan LathaSVP Chief Financial Officer85,978May 13, 20265
Edwards Larry ToddSee Remarks175,178Mar 3, 20264
Chaudhuri BhaskarDirector867,826Jun 16, 20250
Topper David JosephChief Financial Officer182,774Apr 3, 20250
Moore Matthew RichardSVP and Chief Business Officer145,505May 3, 20240
Smither John WChief Financial Officer11,365Feb 15, 20240
Topper James N10% Owner8,764,232Oct 26, 20230
Frazier Life Sciences VIII, L.P.10% Owner8,764,232Oct 26, 20230
FHM Life Sciences VIII, L.P.10% Owner8,764,232Oct 26, 20230
FHM Life Sciences VIII, L.L.C.10% Owner8,764,232Oct 26, 20230
Osborne David WChief Technical Officer268,854Mar 8, 20230
Turney Patricia A.SVP, Operations62,862Mar 8, 20230
Lock Kenneth A.Chief Commercial Officer63,429Mar 8, 20230
Burrows Scott LChief Financial Officer59,115Mar 8, 20230
OrbiMed Advisors LLC10% Owner415,142IndirectJun 28, 20220
OrbiMed Capital LLC10% Owner415,142IndirectJun 28, 20220
OrbiMed Capital GP VII LLC10% Owner415,142IndirectJun 28, 20220
Turner Joseph LDirector4,312Jun 3, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jul 6, 2021 (view filing)Jul 15 daysWelgus Howard G.DirectorSSale−2.20K$26.13−$57.5K−1.2%181.9K after2 lots
Jul 8, 2021 (view filing)Jul 62 daysWatanabe Todd FranklinPresident and CEOSSale−1.75K$26.58−$46.5K−0.3%594.8K after
Aug 9, 2021 (view filing)Aug 54 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$20.81−$20.8K−0.2%594.8K after
Sep 3, 2021 (view filing)Sep 12 daysWelgus Howard G.DirectorSSale−5.00K$20.80−$104.0K−2.7%181.9K after2 lots
Sep 9, 2021 (view filing)Sep 72 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.14−$21.1K−0.2%594.8K after
Oct 5, 2021 (view filing)Oct 14 daysWatanabe Todd FranklinPresident and CEOSSale−1.50K$25.01−$37.5K−0.3%594.8K after
Oct 5, 2021 (view filing)Oct 14 daysWelgus Howard G.DirectorSSale−2.50K$23.87−$59.7K−1.4%181.9K after
Oct 7, 2021 (view filing)Oct 52 daysWatanabe Todd FranklinPresident and CEOSSale−2.50K$24.92−$62.3K−0.4%594.8K after
Nov 3, 2021 (view filing)Nov 12 daysWelgus Howard G.DirectorSSale−2.50K$21.81−$54.5K−1.4%181.9K after
Nov 9, 2021 (view filing)Nov 54 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.50−$21.5K−0.2%594.8K after
Dec 10, 2021 (view filing)Dec 82 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$17.00−$17.0K−0.2%594.8K after
Dec 23, 2021 (view filing)Dec 23Same dayWelgus Howard G.DirectorSSale−2.50K$20.16−$50.4K−1.4%181.9K after
Dec 28, 2021 (view filing)Dec 271 dayBurrows Scott LChief Financial OfficerSSale−12.6K$20.07−$252.1K−35.6%22.7K after
Jan 5, 2022 (view filing)Jan 32 daysWelgus Howard G.DirectorSSale−2.50K$21.21−$53.0K−1.4%181.9K after
Jan 7, 2022 (view filing)Jan 52 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.59−$21.6K−0.2%594.8K after3 lots
Feb 11, 2022 (view filing)Feb 92 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$17.00−$17.0K−0.2%594.8K after
Mar 3, 2022 (view filing)Mar 12 daysLock Kenneth A.Chief Commercial OfficerSSale−935$17.75−$16.6K−2.9%31.7K after
Mar 3, 2022 (view filing)Mar 12 daysTurney Patricia A.SVP, OperationsSSale−936$17.75−$16.6K−4.7%18.8K after
Mar 3, 2022 (view filing)Mar 12 daysBurrows Scott LChief Financial OfficerSSale−420$17.75−$7.46K−1.9%22.3K after
Mar 3, 2022 (view filing)Mar 12 daysOsborne David WChief Technical OfficerSSale−775$17.75−$13.8K−0.3%247.0K after
Mar 3, 2022 (view filing)Mar 12 daysWatanabe Todd FranklinPresident and CEOSSale−2.15K$17.75−$38.2K−0.4%592.6K after
Mar 7, 2022 (view filing)Mar 4-73 daysOsborne David WChief Technical OfficerSSale−856$16.85−$14.4K−0.3%259.4K after2 lots
Mar 7, 2022 (view filing)Mar 4-73 daysTurney Patricia A.SVP, OperationsSSale−1.02K$16.85−$17.2K−3.2%31.1K after2 lots
Mar 7, 2022 (view filing)Mar 4-73 daysBurrows Scott LChief Financial OfficerSSale−303$16.85−$5.10K−0.9%35.3K after2 lots
Mar 7, 2022 (view filing)Mar 4-73 daysLock Kenneth A.Chief Commercial OfficerSSale−1.02K$16.85−$17.2K−2.3%44.0K after2 lots
Mar 7, 2022 (view filing)Mar 4-73 daysBurnett PatrickSee RemarksSSale−1.01K$16.85−$17.0K−2.3%43.0K after2 lots
Mar 7, 2022 (view filing)Mar 4-73 daysWatanabe Todd FranklinPresident and CEOSSale−3.26K$16.90−$55.1K−0.5%661.0K after3 lots
Mar 11, 2022 (view filing)Mar 92 daysWatanabe Todd FranklinPresident and CEOSSale−300$17.00−$5.10K0.0%660.7K after
Apr 1, 2022 (view filing)Apr 1Same dayWelgus Howard G.DirectorSSale−7.50K$20.02−$150.2K−4.0%181.9K after
Apr 5, 2022 (view filing)Apr 5Same dayWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.43−$21.4K−0.2%659.7K after
Apr 8, 2022 (view filing)6:06 PM ETApr 6-82 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−878.2K$20.68−$18.2M−66.1%451.1K after6 lots
Apr 21, 2022 (view filing)Apr 21Same dayOsborne David WChief Technical OfficerSSale−2.20K$20.42−$44.9K−0.8%257.2K after
May 3, 2022 (view filing)May 21 dayWelgus Howard G.DirectorSSale−2.50K$20.44−$51.1K−1.4%181.9K after
May 5, 2022 (view filing)May 5Same dayWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.76−$21.8K−0.2%658.7K after
Jun 2, 2022 (view filing)Jun 11 dayWelgus Howard G.DirectorSSale−2.50K$20.62−$51.5K−1.4%181.9K after
Jun 2, 2022 (view filing)Jun 2Same dayMatsuda MasaruSVP and General CounselSSale−1.79K$19.73−$35.4K−9.9%16.4K after
Jun 6, 2022 (view filing)Jun 6Same dayWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.06−$21.1K−0.2%659.3K after
Jun 28, 2022 (view filing)4:29 PM ETJun 244 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−342.0K$21.31−$7.29M−45.2%415.1K after2 lots
Jul 7, 2022 (view filing)Jul 61 dayWatanabe Todd FranklinPresident and CEOSSale−1.00K$22.07−$22.1K−0.2%658.3K after
Jul 12, 2022 (view filing)Jul 84 daysWatanabe Todd FranklinPresident and CEOSSale−13.5K$25.36−$342.4K−2.0%651.9K after3 lots
Jul 12, 2022 (view filing)Jul 84 daysOsborne David WChief Technical OfficerSSale−2.20K$25.41−$55.8K−0.8%256.6K after
Jul 18, 2022 (view filing)Jul 18Same dayWelgus Howard G.DirectorSSale−6.00K$24.40−$146.4K−3.2%180.2K after
Aug 9, 2022 (view filing)Aug 54 daysWatanabe Todd FranklinPresident and CEOSSale−2.50K$24.74−$61.9K−0.4%651.9K after
Aug 9, 2022 (view filing)4:34 PM ETAug 54 daysHeron Patrick J and 4 othersDirector, 10% OwnerPPurchase+250.0K$20.00+$5.00M+3.0%8.68M after
Aug 17, 2022 (view filing)Aug 152 daysWelgus Howard G.DirectorSSale−6.00K$24.80−$148.8K−3.3%174.2K after
Sep 9, 2022 (view filing)Sep 72 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$21.51−$21.5K−0.3%381.9K after
Oct 6, 2022 (view filing)Oct 42 daysWelgus Howard G.DirectorSSale−6.00K$20.29−$121.7K−3.4%168.2K after
Oct 11, 2022 (view filing)Oct 74 daysWatanabe Todd FranklinPresident and CEOSSale−1.00K$19.51−$19.5K−0.3%380.9K after
Nov 9, 2022 (view filing)Nov 72 daysWatanabe Todd FranklinSee RemarksSSale−1.00K$18.00−$18.0K−0.3%379.9K after
Nov 17, 2022 (view filing)Nov 152 daysWelgus Howard G.DirectorSSale−3.40K$20.01−$68.1K−2.0%165.8K after